CYP2D6-DEBRISOQUINE HYDROXYLASE GENE POLYMORPHISM IN MULTIPLE SYSTEM ATROPHY

被引：14
|
作者：
PLANTEBORDENEUVE, V
BANDMANN, O
WENNING, G
QUINN, NP
DANIEL, SE
HARDING, AE
机构：
[1] UNIV LONDON,INST NEUROL,DEPT CLIN NEUROL,NEUROGENET SECT,LONDON WC1N 3BG,ENGLAND
[2] UNIV LONDON,INST NEUROL,DEPT CLIN NEUROL,MOVEMENT DISORDERS SECT,LONDON WC1N 3BG,ENGLAND
[3] UNIV LONDON,INST NEUROL,DEPT CLIN NEUROL,PARKINSONS DIS SOC BRAIN BANK,LONDON WC1N 3BG,ENGLAND
来源：
MOVEMENT DISORDERS | 1995年 / 10卷 / 03期
关键词：
MULTIPLE SYSTEM ATROPHY; CYTOCHROME P450; PARKINSONS DISEASE;
D O I：
10.1002/mds.870100307
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Molecular genetic studies of the cytochrome P450 system enzyme CYP2D6, which hydroxylates debrisoquine, have indicated an excess of mutant yaffles in large series of patients with Parkinson's disease (PD) when compared with controls. We have investigated CYP2D6 polymorphism in 91 patients with multiple system atrophy (MSA) in order to determine if this finding is specific to PD or if there is similar evidence of genetic susceptibility to neurotoxicity in MSA. The distribution of CYP2D6 alleles was not significantly different between MSA patients and controls, and there were fewer poor metabolisers in the MSA group than in the control group.
引用
收藏
页码：277 / 278
页数：2
相关论文
共 50 条
  • [21] Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations
    S. Wanwimolruk
    S. Bhawan
    P. F. Coville
    S. C. W. Chalcroft
    European Journal of Clinical Pharmacology, 1998, 54 : 431 - 435
  • [22] Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations
    Wanwimolruk, S
    Bhawan, S
    Coville, PF
    Chalcroft, SCW
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (05) : 431 - 435
  • [23] ENDOGENOUS CODEINE AND MORPHINE IN POOR AND EXTENSIVE METABOLIZERS OF THE CYP2D6 (DEBRISOQUINE/SPARTEINE) POLYMORPHISM
    MIKUS, G
    BOCHNER, F
    EICHELBAUM, M
    HORAK, P
    SOMOGYI, AA
    SPECTOR, S
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1994, 268 (02): : 546 - 551
  • [24] LUNG-CANCER AND CYP2D6 (THE DEBRISOQUINE POLYMORPHISM) - SOURCES OF HETEROGENEITY IN THE PROPOSED ASSOCIATION
    CAPORASO, N
    DEBAUN, MR
    ROTHMAN, N
    PHARMACOGENETICS, 1995, 5 : S129 - S134
  • [25] DEBRISOQUINE OXIDATION POLYMORPHISM - PHENOTYPIC CONSEQUENCES OF A 3-BASE-PAIR DELETION IN EXON 5 OF THE CYP2D6 GENE
    BROLY, F
    MEYER, UA
    PHARMACOGENETICS, 1993, 3 (03): : 123 - 130
  • [26] Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population - Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6
    Masimirembwa, C
    Hasler, J
    Bertilssons, L
    Johansson, I
    Ekberg, O
    IngelmanSundberg, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 51 (02) : 117 - 122
  • [27] DEBRISOQUINE POLYMORPHISM - NOVEL CYP2D6 GENE BAM HI RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM IN THE NGAWBE-GUAYMI INDIAN OF PANAMA
    PETERSEN, DD
    KONG, ANT
    JORGE, LF
    NEBERT, DW
    ARIAS, TD
    PHARMACOGENETICS, 1991, 1 (03): : 136 - 142
  • [28] Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis
    Siddons, MA
    PickeringBrown, SM
    Mann, DMA
    Owen, F
    Cooper, PN
    NEUROSCIENCE LETTERS, 1996, 208 (01) : 65 - 68
  • [29] Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B
    Kawanishi, C
    Hanihara, T
    Maruyama, Y
    Matsumura, T
    Onishi, H
    Inoue, K
    Sugiyama, N
    Suzuki, K
    Yamada, Y
    Kosaka, K
    PSYCHIATRIC GENETICS, 1997, 7 (03) : 127 - 129
  • [30] DEBRISOQUINE 4-HYDROXYLASE (CYP2D) LOCUS AND POSSIBLE SUSCEPTIBILITY TO SCHIZOPHRENIA
    VALLADA, H
    COLLIER, D
    DAWSON, E
    OWEN, M
    NANKO, S
    MURRAY, R
    GILL, M
    LANCET, 1992, 340 (8812): : 181 - 182
12345